Competitive Salary: EMBL: Data Coordination and Archiving Presentation Technology Project Lead Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Bioinformatics Developer Location: Cambridge, Cambridgeshire, England

(4) Laboratory expertise with nucleic acid microarrays, next gen sequencing, STR analysis, aptamers, bioinformatics, and data analysis is a plus; $20 - $30 an hour
From Indeed - Fri, 11 Dec 2020 22:15:28 GMT - View all Madison, WI jobs

Competitive Salary: F. Hoffmann-La Roche AG: At Roche we believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about Switzerland (CH)

Notice NOT-OD-21-041 from the NIH Guide for Grants and Contracts

Notice NOT-OH-21-008 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-023 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-019 from the NIH Guide for Grants and Contracts

range £36,028 – £40,125 per annum including London Allowance, superannuable: University College London (UCL): Applications are invited for a Research Fellow Biostatistician in the Department of Clinical and Experimental Epilepsy... London (Central), London (Greater)

Degree in biomedical, social, behavioral sciences, public health, bioinformatics, computer science or related field, preferred.
From University of Wisconsin–Madison - Fri, 11 Dec 2020 06:57:33 GMT - View all Madison, WI jobs

Notice NOT-CA-21-022 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-097 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider FOA (PAR-21-NNN, the R61/R33 option).

Funding Opportunity PAR-21-098 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and that (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider FOA (PAR-21-NNN, the R34 option).

Notice NOT-OD-21-040 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-064 from the NIH Guide for Grants and Contracts. The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting welldesigned and wellexecuted clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, has annual direct costs equal to or greater than $500,000, that is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm. Clinical trial applications exceeding the annual direct costs of $700,000 or more may also be a criteria for this FOA. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed in each NIDCD Clinical Trials in Communication Disorders U01 application.

Funding Opportunity PAR-21-063 from the NIH Guide for Grants and Contracts. The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity announcement (FOA) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm. This FOA also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred companion U01 FOA PAR-21-XXX, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.

The successful candidate will be knowledgeable in biological science concepts, particularly in molecular evolution, and have experience in the preparation of…
From University of Wisconsin–Madison - Fri, 11 Dec 2020 00:57:28 GMT - View all Madison, WI jobs

Funding Opportunity RFA-ES-21-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R43) SBIR grant applications from small business concerns (SBCs) to develop promising methodologies using Artificial Intelligence (AI) and Machine Learning (ML) approaches to advance environmental health research and decisions. When developed and validated, these methodologies or approaches will further advance the accuracy of toxicity prediction, help in prioritizing chemicals for more relevant or targeted testing, identify and/or fill data or knowledge gaps in toxicity assessment, promote more comprehensive understanding of human exposures, susceptibility and adverse health outcomes.

Funding Opportunity RFA-ES-21-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R43) SBIR grant applications from small business concerns (SBCs) to develop promising methodologies using Artificial Intelligence (AI) and Machine Learning (ML) approaches to advance environmental health research and decisions. When further developed and validated, these methodologies or approaches should improve the accuracy of toxicity prediction, help in prioritizing chemicals for more relevant or targeted testing, identify and/or fill data or knowledge gaps in toxicity assessment, and promote more comprehensive understanding of human exposure effects, susceptibility and adverse health outcomes.

Competitive Salary: F. Hoffmann-La Roche AG: At Roche we believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about trans Switzerland (CH)